Aptamer-modified Nanocarrier(s) for the Management of Prostate Cancer

Abstract

Abstract: Prostate cancer remains a significant global health concern, necessitating the development of innovative therapeutic approaches. This editorial provides an overview of the current state of research on aptamer-modified nanocarriers as a novel strategy for prostate cancer therapy. Aptamers, known for their high specificity and affinity, have drawn much attention in both research and the pharmaceutical industry. The Systematic Evolution of Ligands by the Exponential Enrichment (SELEX) technique has enabled the development of aptamers that can selectively bind to target ligands based on their unique three-dimensional structures. Notably, the A10 aptamer, modified to target PSMA (Prostate-Specific Membrane Antigen), has demonstrated strong binding affinity and specificity to prostate cancer cells, offering promise as an efficient drug-delivery system. Additionally, biosensors, like the innovative apta-sensor targeting MUC1, have utilized aptamers to detect cancer through electrochemical signals. Additionally, aptamers have improved the pharmacological attributes of chemotherapeutic agents for prostate cancer treatment. Aptamer-- mediated drug delivery has offered enhanced drug delivery, targeting, cellular uptake, and minimizing side effects.